Clinical Trial

A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2302 versus Tezspire®（Tezepelumab） in healthy subjects after a single dose.
Trial Details
NCT Number NCT07327697
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Healthy Participants
Enrollment 178 participants
Start Date 2025-12-22
Primary Completion 2026-07 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-08